Lipoprotein a inhibitor - Eli Lilly and Company
Alternative Names: Lp(a) inhibitor - Eli Lilly and CompanyLatest Information Update: 28 Jun 2024
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Cardiovascular therapies; Small molecules
- Mechanism of Action Lipoprotein A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Diabetes mellitus
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Cardiovascular-disorders in USA
- 28 Jun 2024 No recent reports of development identified for phase-I development in Diabetes-mellitus in USA
- 05 May 2021 Phase-I clinical trials in Cardiovascular disorders in USA (unspecified route), prior to May 2021 (Eli Lilly and Company pipeline, May 2021)